{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:32:16Z","timestamp":1791484336034,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40263-024-01140-w","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T16:22:44Z","timestamp":1735316564000},"page":"127-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and Efficacy of Ecopipam in Patients with Tourette Syndrome: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"39","author":[{"given":"Prateek Kumar","family":"Panda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragnya","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesa","family":"Dawman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand Santosh","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-7218","authenticated-orcid":false,"given":"Indar Kumar","family":"Sharawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"1140_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/brain\/awx204","volume":"141","author":"RL Albin","year":"2018","unstructured":"Albin RL. Tourette syndrome: a disorder of the social decision-making network. Brain. 2018;141:332\u201347.","journal-title":"Brain"},{"key":"1140_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/02698811211032445","volume":"35","author":"FM Besag","year":"2021","unstructured":"Besag FM, Vasey MJ, Lao KS, Chowdhury U, Stern JS. Pharmacological treatment for Tourette syndrome in children and adults: what is the quality of the evidence? A systematic review. J Psychopharmacol. 2021;35:1037\u201361.","journal-title":"J Psychopharmacol"},{"key":"1140_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00787-021-01854-y","volume":"31","author":"SM Anderson","year":"2022","unstructured":"Anderson SM. Tics and Tourette Around the Globe (TTAG) representing Tic and Tourette Syndrome (TS) patient associations around the world. European clinical guidelines for Tourette Syndrome and other tic disorders: patients\u2019 perspectives on research and treatment. Eur Child Adolesc Psychiatry. 2022;31:463\u20139.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1140_CR4","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s13311-020-00914-6","volume":"17","author":"A Billnitzer","year":"2020","unstructured":"Billnitzer A, Jankovic J. Current management of tics and Tourette syndrome: behavioral, pharmacologic, and surgical treatments. Neurotherapeutics. 2020;17:1681\u201393.","journal-title":"Neurotherapeutics"},{"key":"1140_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101998","volume":"24","author":"S Ramkiran","year":"2019","unstructured":"Ramkiran S, Heidemeyer L, Gaebler A, Shah NJ, Neuner I. Alterations in basal ganglia-cerebello-thalamo-cortical connectivity and whole brain functional network topology in Tourette\u2019s syndrome. Neuroimage Clin. 2019;24: 101998.","journal-title":"Neuroimage Clin."},{"key":"1140_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bj.2022.01.008","volume":"45","author":"WD Lin","year":"2022","unstructured":"Lin WD, Tsai FJ, Chou IC. Current understanding of the genetics of Tourette syndrome. Biomed J. 2022;45:271\u20139.","journal-title":"Biomed J"},{"key":"1140_CR7","doi-asserted-by":"publisher","first-page":"S29.e15-22","DOI":"10.1016\/j.wneu.2012.06.017","volume":"80","author":"L Ackermans","year":"2013","unstructured":"Ackermans L, Kuhn J, Neuner I, Temel Y, Visser-Vandewalle V. Surgery for Tourette syndrome. World Neurosurg. 2013;80:S29.e15-22.","journal-title":"World Neurosurg"},{"key":"1140_CR8","doi-asserted-by":"publisher","first-page":"12387","DOI":"10.1523\/JNEUROSCI.0150-11.2011","volume":"31","author":"RJ Felling","year":"2011","unstructured":"Felling RJ, Singer HS. Neurobiology of Tourette syndrome: current status and need for further investigation. J Neurosci. 2011;31:12387\u201395.","journal-title":"J Neurosci"},{"key":"1140_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ncl.2014.09.008","volume":"33","author":"C Ganos","year":"2015","unstructured":"Ganos C, Martino D. Tics and Tourette syndrome. Neurol Clin. 2015;33:115\u201336.","journal-title":"Neurol Clin"},{"key":"1140_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/WCO.0000000000000575","volume":"31","author":"A Hartmann","year":"2018","unstructured":"Hartmann A, Worbe Y. Tourette syndrome: clinical spectrum, mechanisms and personalized treatments. Curr Opin Neurol. 2018;31:504\u20139.","journal-title":"Curr Opin Neurol"},{"key":"1140_CR11","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-059574","volume":"151","author":"DL Gilbert","year":"2023","unstructured":"Gilbert DL, Dubow JS, Cunniff TM, Wanaski SP, Atkinson SD, Mahableshwarkar AR. Ecopipam for Tourette syndrome: a randomized trial. Pediatrics. 2023;151: e2022059574.","journal-title":"Pediatrics"},{"key":"1140_CR12","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/mds.27457","volume":"33","author":"DL Gilbert","year":"2018","unstructured":"Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, et al. Ecopipam, a D1 receptor antagonist, for treatment of Tourette syndrome in children: a randomized, placebo-controlled crossover study. Mov Disord. 2018;33:1272\u201380.","journal-title":"Mov Disord"},{"key":"1140_CR13","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.12688\/f1000research.15558.1","volume":"7","author":"A Hartmann","year":"2018","unstructured":"Hartmann A, Worbe Y, Black KJ. Tourette syndrome research highlights from 2017. F1000Res. 2018;7:1122.","journal-title":"F1000Res"},{"key":"1140_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339: b2700.","journal-title":"BMJ"},{"key":"1140_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"1140_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"1140_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/WNF.0000000000000017","volume":"37","author":"DL Gilbert","year":"2014","unstructured":"Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE. A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014;37:26\u201330.","journal-title":"Clin Neuropharmacol"},{"key":"1140_CR18","unstructured":"Emalex Biosciences Inc. A multicenter, open-label, extension study intended to evaluate the long-term safety of ecopipam tablets in children and adolescent subjects with Tourette\u2019s syndrome [Internet]. clinicaltrials.gov; 2024. Report No.: NCT04114539. https:\/\/clinicaltrials.gov\/study\/NCT04114539. Accessed 1 Jan 2024."},{"key":"1140_CR19","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1212\/WNL.0000000000202081","volume":"100","author":"S Freidy","year":"2023","unstructured":"Freidy S, Dumitrescu T, Schmith V, Gilbert D, Mahableshwarkar A, Dubow J, et al. Increasing ecopipam exposure improves yale global tic severity scale-total tic scores (YGTSS-TTS) in children and adolescents with Tourette syndrome (TS): results from a population pharmacokinetic (popPK) model-based simulation using D1AMOND trial data (P5-9.007). Neurology. 2023;100:1722.","journal-title":"Neurology"},{"key":"1140_CR20","unstructured":"Emalex Biosciences Inc. Ecopipam Treatment of Tourette\u2019s Syndrome in Subjects 7-17 Years [Internet]. clinicaltrials.gov; 2024. Report No.: NCT02102698. https:\/\/clinicaltrials.gov\/study\/NCT02102698. Accessed 1 Jan 2024."},{"key":"1140_CR21","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/WNL.0000000000202165","volume":"100","author":"T Cunniff","year":"2023","unstructured":"Cunniff T, Gilbert D, Wanaski S, Bittman R, Dubow J, Mahableshwarkar A. Design of a phase 3 maintenance-of-effect trial of ecopipam in Tourette syndrome (P12\u201311.011). Neurology. 2023;100:1863.","journal-title":"Neurology"},{"key":"1140_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.braindev.2014.11.005","volume":"37","author":"M Hallett","year":"2015","unstructured":"Hallett M. Tourette syndrome: update. Brain Dev. 2015;37:651\u20135.","journal-title":"Brain Dev"},{"key":"1140_CR23","first-page":"401","volume":"25","author":"MF Seideman","year":"2020","unstructured":"Seideman MF, Seideman TA. A review of the current treatment of Tourette syndrome. J Pediatr Pharmacol Ther. 2020;25:401\u201312.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"1140_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S2352-4642(22)00316-9","volume":"7","author":"LC Farhat","year":"2023","unstructured":"Farhat LC, Behling E, Landeros-Weisenberger A, Levine JLS, MaculFerreiradeBarros P, Wang Z, et al. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette\u2019s syndrome: a systematic review and network meta-analysis. Lancet Child Adolesc Health. 2023;7:112\u201326.","journal-title":"Lancet Child Adolesc Health"},{"key":"1140_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/NDT.S12990","volume":"8","author":"D Huys","year":"2012","unstructured":"Huys D, Hardenacke K, Poppe P, Bartsch C, Baskin B, Kuhn J. Update on the role of antipsychotics in the treatment of Tourette syndrome. Neuropsychiatr Dis Treat. 2012;8:95\u2013104.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1140_CR26","first-page":"7","volume":"28","author":"N Dutta","year":"2013","unstructured":"Dutta N, Cavanna AE. The effectiveness of habit reversal therapy in the treatment of Tourette syndrome and other chronic tic disorders: a systematic review. Funct Neurol. 2013;28:7\u201312.","journal-title":"Funct Neurol"},{"key":"1140_CR27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.28957","volume":"37","author":"E Behling","year":"2022","unstructured":"Behling E, Farhat LC, Landeros-Weisenberger A, Bloch MH. Meta-Analysis: efficacy and tolerability of vesicular monoamine transporter type 2 inhibitors in the treatment of tic disorders. Mov Disord. 2022;37:684\u201393.","journal-title":"Mov Disord"},{"key":"1140_CR28","doi-asserted-by":"crossref","unstructured":"Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-Blind, crossover trial.  J Am Acad Child Adolesc Psychiatry. 2004;43:206\u201314.","DOI":"10.1097\/00004583-200402000-00017"},{"key":"1140_CR29","doi-asserted-by":"crossref","unstructured":"Yoo HK, Lee JS, Paik KW, Choi SH, Yoon SJ, Kim JE, et al. Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. Eur Child Adolesc Psychiatry. 2011;20:127\u201335.","DOI":"10.1007\/s00787-010-0154-0"},{"key":"1140_CR30","doi-asserted-by":"crossref","unstructured":"Karlsson P, Smith L, Farde L, H\u00e4rnryd C, Sedvall G, Wiesel FA. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl). 1995;121:309\u201316.","DOI":"10.1007\/BF02246068"},{"key":"1140_CR31","doi-asserted-by":"crossref","unstructured":"Godar SC, Mosher LJ, Strathman HJ, Gochi AM, Jones CM, Fowler SC, et al. The D1CT\u20107 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement. Br J Pharmacol. 2016;173:2111\u201321.","DOI":"10.1111\/bph.13243"},{"key":"1140_CR32","doi-asserted-by":"crossref","unstructured":"Jeon S, Walkup JT, Woods DW, Peterson A, Piacentini J, Wilhelm S, et al. Detecting a clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methods. Contemp Clin Trials. 2013;36:414\u201320.","DOI":"10.1016\/j.cct.2013.08.012"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01140-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01140-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01140-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T14:53:44Z","timestamp":1737903224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01140-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01140-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"21 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board of All India Institute of Medical Sciences, Rishikesh, India (AIIMS\/IEC\/24\/401, Date-29 June 2024).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Data can be provided by the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"P.K.P., I.K.S., L.D., A.S.M., and P.P. were involved in the conception, acquisition, analysis, and interpretation of data; P.K.P. and I.K.S. did initial search; L.D. and P.P. performed full text review; P.K.P., L.D., A.S.M., V.K., and I.K.S. drafted the initial draft; P.P. performed the statistical analysis; I.K.S., A.S.M., and V.K. critically revised the manuscript. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}}]}}